Kolexia
Penot Amelie Hématologie
Penot Amelie
Hématologie
Hôpital Dupuytren
Limoges, France
33 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie myéloïde chronique BCR-ABL positive Leucémies Leucémie myéloïde Tumeurs hématologiques Lymphome malin non hodgkinien Lymphomes Thrombocytémie essentielle Amyloïdose Hémorragie

Collaborateurs

Voir plus
Dmytruk Natalia
Dmytruk Natalia
Hôpital Dupuytren, Limoges, France
Abraham Julie
Abraham Julie
Hôpital Dupuytren, Limoges, France
Jaccard Arnaud
Jaccard Arnaud
Hôpital Dupuytren, Limoges, France
Coiteux Valérie
Coiteux Valérie
Hôpital Huriez, Lille, France

Industries

Voir plus
Novartis
16 collaboration(s)
Dernière en 2023
Janssen
8 collaboration(s)
Dernière en 2023
Abbvie
1 collaboration(s)
Dernière en 2023
Accord Healthcare
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System: Discontinuation of TyrosIne Kinase Inhibitors (ITK) in Chronic Myeloid Leukemia (LMC) and Impact on the Immune System: a Randomized Comparative Study of Two Therapeutic Strategies
Essai Clinique (CHU Poitiers)   19 mars 2024
BIO-TIMER: Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated With Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.
Essai Clinique (CHU Clermont-Ferrand)   29 février 2024
Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence
65th ASH Annual Meeting Abstracts   02 novembre 2023
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Essai Clinique (CHU Brest)   27 octobre 2023
Chronic Myeloid Leukemia (CML) Real-Life Database
Essai Clinique (CHU Clermont-Ferrand)   18 juillet 2023
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Leukemia   22 janvier 2021
ACTIW: Candidate Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors in Chronic Phase-chronic Myelogenous Leukemia Patients in CCR Without Achieving a Deep Molecular Response: an Adaptative Trial Based on a Drop Loser Design
Essai Clinique (Centre hospitalier de Versailles)   06 août 2020
Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy: Observational single-center study of 122 patients.
Journal of geriatric oncology   26 août 2017
Quels sont les signes clinico-biologiques permettant d’évoquer le diagnostic de lymphome non-Hodgkinien de type T ?
71e CONGRÈS DE LA SOCIÉTÉ NATIONALE FRANÇAISE DE MÉDECINE INTERNE, Besançon, 10-12 juin 2015   01 juin 2015